Literature DB >> 4140196

Specificity of heteroantisera to human acute leukemia-associated antigens.

M A Baker, K Ramachandar, R N Taub.   

Abstract

Antisera have been raised to human leukemic blast cells from individual patients in mice rendered tolerant with cyclophosphamide to remission leukocytes from the same individual. 10 antisera were raised against acute myelogenous leukemia (AML) cells and 5 antisera were raised against acute lymphoblastic leukemia (ALL) cells. Antisera to AML cells were absorbed with ALL cells, and antisera to ALL cells were absorbed with AML cells. Unabsorbed and absorbed antisera as well as antisera raised in nontolerant mice were tested for cytotoxicity against various cells of a panel containing myeloblasts from 35 patients with AML, lymphoblasts from 7 patients with ALL, myeloblasts from 7 patients with chronic myelogenous leukemia (CML) in blast crisis, peripheral blood leukocytes from 12 patients with acute leukemia in remission and 30 nonleukemic patients, and nucleated bone marrow cells from 10 nonleukemic patients. Unabsorbed antisera to AML or ALL cells raised in tolerant mice were highly cytotoxic to leukemic blasts cells but significantly less cytotoxic to remission and control cells. Antisera to AML cells absorbed with ALL cells retained measurable cytotoxicity against AML cells but were not cytotoxic to ALL cells or control cells. Similarly, antisera to ALL cells absorbed with AML cells retained significant cytotoxicity only to ALL cells. Control antisera raised in nontolerant mice were cytotoxic to all cells tested. Although species specific, histocompatibility, differentiation, maturation, and cell cycle-associated antigens may be responsible in part for the cytotoxic activity of the unabsorbed antisera, the absorbed antisera are probably detecting antigens specific for their leukemic cell type.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4140196      PMCID: PMC301680          DOI: 10.1172/JCI107872

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  HL-A antigens on leukaemic cells.

Authors:  G D Pegrum; I C Balfour; C A Evans; V L Middleton
Journal:  Br J Haematol       Date:  1970-10       Impact factor: 6.998

2.  Reticulocyte HL-A antigens.

Authors:  R Harris; J D Zervas
Journal:  Nature       Date:  1969-03-15       Impact factor: 49.962

3.  Differential immune lysis of erythroblasts.

Authors:  H Borsook; K Ratner; B Tattrie
Journal:  Nature       Date:  1969-03-29       Impact factor: 49.962

4.  Antibody to rabbit reticulocytes.

Authors:  H M Schulman; R A Nelson
Journal:  Nature       Date:  1969-08-09       Impact factor: 49.962

5.  The potentiality of out-of-cycle acute leukemic cells to synthesize DNA.

Authors:  P Stryckmans; G Delalieux; J Manaster; M Socquet
Journal:  Blood       Date:  1970-12       Impact factor: 22.113

6.  Acute childhood leukaemia in relation to the HL-A human transplantation genes.

Authors:  R L Walford; S Finkelstein; R Neerhout; P Konrad; E Shanbrom
Journal:  Nature       Date:  1970-01-31       Impact factor: 49.962

7.  Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody.

Authors:  E A Boyse; E Stockert; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

8.  Demonstration by immunoelectrophoresis of antigen in human myelogenous leukemia.

Authors:  R M Hyde; S Garb; A J Bennett
Journal:  J Natl Cancer Inst       Date:  1967-06       Impact factor: 13.506

9.  The detection of iso-antigens on leukemic cells using the cytotoxicity test.

Authors:  I Peacocke; B Amos; J Laszlo
Journal:  Blood       Date:  1966-11       Impact factor: 22.113

10.  Solubilization and partial purification of human leukaemic specific antigens.

Authors:  D Viza; D A Davies; R Harris
Journal:  Nature       Date:  1970-09-19       Impact factor: 49.962

View more
  6 in total

Review 1.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.

Authors:  J M Jaso; S A Wang; J L Jorgensen; P Lin
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

2.  Antisera against leukaemia-associated antigens on human lymphocytes.

Authors:  C C Hsu; G E Marti; K K Mittal
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

3.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

4.  Clinical relevance of circulating immune complexes in human leukemia. Association in acute leukemia of the presence of immune complexes with unfavorable prognosis.

Authors:  N A Carpentier; G T Lange; D M Fiere; G J Fournie; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

Review 5.  MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?

Authors:  Ilias Pessach; Theodoros Spyropoulos; Eleftheria Lamprianidou; Ioannis Kotsianidis
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

6.  Cytotoxic antibody in acute myeloblastic leukaemia during immunotherapy: lack of tumour specificity.

Authors:  D G Gale; I C MacLennan
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.